Papaverine with chemoradiation for stage II–III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This early-phase trial tests whether adding papaverine to standard chemoradiation can improve treatment for stage II–III non-small cell lung cancer (and some limited stage IV cases). It aims to see if the combination is safe and tolerable while targeting the cancer with radiation and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer that is stage II–III, or limited stage IV (with up to 5–10 specific sites, excluding how brain spots are counted).
- Your body can handle treatment: blood counts are high enough (neutrophils, hemoglobin, platelets) and certain liver and kidney tests are within limits.
- You have no serious lasting side effects from past treatment—any prior treatment-related toxicities must be mild (grade 1 or less), except hair loss.
- You must have had recent scans (PET-CT or CT with contrast, and MRI brain with contrast preferred) as part of your work-up.
- You can get standard chemotherapy with radiation during the study, and you are not expected to need surgery that would change treatment plans.
- You are generally able to consent and participate (ECOG performance status 0–2), with no major medical conditions that would make treatment unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
This trial studies adding focused radiation to some cancer spots in people with stage III non-small cell lung cancer (NSCLC) whose cancer did not fully stop after standard chemoradiation and durvalumab. The goal is to control a small number of growing spots (or more than a few) and improve outcomes after durvalumab.
This trial tests a new drug, JNJ-90301900, given together with standard chemotherapy and radiation, followed by maintenance immunotherapy (durvalumab) for people with stage 3 non-small cell lung cancer that cannot be surgically removed. The goal is to see if adding this drug improves outcomes.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether giving a combination of two immunotherapy drugs with chemotherapy before surgery can help shrink stage III lung cancer and improve outcomes. It is for people whose cancer has spread to lymph nodes in the chest but can still be removed with surgery.
Hear when a new Locally Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.